Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01923636

Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero — CYMEPEDIA  

Congenital Cytomegalovirus Infection Clinical Trial

Official title:
Evaluation of the Prognostic Value of Clinical, Imaging, Immunological and Virological Markers in the Neonatal Period for the Development of Neurosensorial Sequelae at 1 Year in Children Infected by Cytomegalovirus in Utero.

Clinical Trial Summary

The main objective of this study is to validate , in the neonatal period, a prognostic score for the development of neurosensorineural sequelae at 1 year and at 2 years in neonates infected in utero by cytomegalovirus. This score will be based on clinical, imaging and biological criteria . The second objective of the study is to estimate the prevalence of this infection in France and to describe its epidemiology through the screening of 12,000 consecutive neonates.

Clinical Trial Description

Infection with cytomegalovirus (CMV) is the most frequent cause of congenital neurological handicap of infectious origin in industrialized countries. Around 10% of infected neonates have symptoms and more than 50% of those will develop long term neurological sequelae and sensorineural hearing loss. Among asymptomatic infected neonates 10 to 15% will ultimately develop hearing loss. To establish the prognosis of infected neonates remains difficult and the purpose of the study is to better define early prognosis factors The true burden of CMV congenital infection is unknown in France: the prevalence of the infection as well as the description of its epidemiology (proportion of symptomatic and asymptomatic cases, rate of long term sequelae, proportion of cases following primary or secondary maternal infections) are unknown. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01923636
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date September 9, 2013
Completion date May 16, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03973359 - Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy N/A
Completed NCT02005822 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Phase 3
Completed NCT02139423 - Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening N/A
Withdrawn NCT02594566 - Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine Phase 1
Completed NCT02351102 - Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Phase 2/Phase 3
Active, not recruiting NCT05170269 - Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) Phase 3
Not yet recruiting NCT06118515 - A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Phase 1
Completed NCT02782988 - Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
Completed NCT02645396 - A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
Terminated NCT01655212 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial Phase 3
Completed NCT02710864 - A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
Completed NCT05754879 - Diagnosis of Congenital Cytomegalovirus Infection in Newborn With Particular Risk
Terminated NCT03301415 - Asymptomatic Congenital CMV Treatment Phase 2
Completed NCT01376778 - A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Phase 3